ArticleFrontiers in oncology2025
Contemporary epidemiological landscape of pediatric non-Hodgkin lymphoma: a global burden of disease analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study evaluated the distribution characteristics, influencing factors, and future trends of non-Hodgkin lymphoma (NHL) burden in children and adolescents globally from 1990 to 2021. Methods: Data were obtained from the Global Burden of Disease Study database. Multiple analytical methods were used, including Joinpoint regression, age-period-cohort analysis, decomposition analysis, frontier analysis, health equity analysis, and Bayesian age-period-cohort (BAPC) model. Results: In 2021, the global age-standardized prevalence rate was 3.177/100,000, with a disability adjusted life year (DALY) rate of 13.535/100,000. The prevalence demonstrated a fluctuating downward trend during 1990-2021. Age, period, and cohort effects significantly influenced disease patterns. While population growth drove prevalence increase, population aging and epidemiological factors had negative impacts. Disease burden showed a non-linear negative correlation with Socio-demographic Index (SDI). Over the past nearly 30 years, health inequality has intensified, as some African regions have shown relatively low prevalence rates due to limited resource Settings, which have restricted disease diagnosis and reporting, compared with the developed areas with high prevalence. The BAPC model predicted further decrease from 2022-2036. Discussion: Despite overall decline, significant regional differences and health inequalities persist, suggesting future focus on targeted prevention, optimized resource allocation, and improved treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.